文献速递临床试验与 GCP

全腹腔镜子宫切除术与全腹式子宫切除术对I期子宫内膜癌患者无病生存期的影响:一项随机临床试验

Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

LACE试验为多国随机等效性试验,2005年10月7日至2010年6月30日纳入760例I期子宫内膜样子宫内膜癌患者,随机接受全腹式子宫切除术(TAH,n=353)或全腹腔镜子宫切除术(TLH,n=407),中位随访4.5年。4.5年无病生存率TAH组81.3% vs TLH组81.6%,率差0.3%(95%CI -5.5%至6.1%,P=.007),符合等效性标准;两组复发和总生存无统计学显著差异。

要点

  • 4.5年无病生存率TAH组81.3% vs TLH组81.6%,率差0.3%(95%CI -5.5%至6.1%),达到预设等效性界值≤7%。
  • 子宫内膜癌复发:TAH组28/353(7.9%)vs TLH组33/407(8.1%),风险差0.2%(95%CI -3.7%至4.0%),无统计学显著差异。
  • 总生存:TAH组24/353(6.8%)vs TLH组30/407(7.4%),风险差0.6%(95%CI -3.0%至4.2%),无统计学显著差异。

核心结论

  • 在I期子宫内膜癌女性中,与全腹腔镜子宫切除术相比,全腹式子宫切除术在4.5年时获得等效的无病生存,且总生存无差异。
  • 这些发现支持对I期子宫内膜癌女性使用腹腔镜子宫切除术。

研究设计与样本

  • LACE试验为多国、随机等效性试验,于2005年10月7日至2010年6月30日开展,由澳大利亚、新西兰和香港20个三级妇科肿瘤中心的27名外科医生随机分配760例I期子宫内膜样子宫内膜癌患者。
  • 患者随机接受全腹式子宫切除术(TAH,n=353)或全腹腔镜子宫切除术(TLH,n=407);随访于2016年3月3日结束。
  • 主要结局为无病生存,定义为手术至首次复发(包括疾病进展或新发原发癌或死亡)的间隔,在随机化后4.5年评估;预设等效性界值为7%或以下。

主要发现

  • 760例随机患者平均年龄63岁,其中679例(89%)完成试验,中位随访4.5年。
  • 4.5年随访时,无病生存率TAH组为81.3%,TLH组为81.6%;无病生存率差为0.3%(支持TLH;95%CI -5.5%至6.1%;P=.007),符合等效性标准。
  • 子宫内膜癌复发:TAH组28/353(7.9%)vs TLH组33/407(8.1%);风险差0.2%(95%CI -3.7%至4.0%;P=.93),无统计学显著组间差异。
  • 总生存:TAH组24/353(6.8%)vs TLH组30/407(7.4%);风险差0.6%(95%CI -3.0%至4.2%;P=.76),无统计学显著组间差异。

关键数值与推荐

  • 预设等效性界值为7%或以下;无病生存率差0.3%(95%CI -5.5%至6.1%)符合等效性标准。
  • 子宫内膜癌复发风险差0.2%(95%CI -3.7%至4.0%;P=.93),无统计学显著差异。
  • 总生存风险差0.6%(95%CI -3.0%至4.2%;P=.76),无统计学显著差异。

临床怎么用

  • 作者结论指出,这些发现支持对I期子宫内膜癌女性使用腹腔镜子宫切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Standard treatment for endometrial cancer involves removal of the uterus, tubes, ovaries, and lymph nodes. Few randomized trials have compared disease-free survival outcomes for surgical approaches. OBJECTIVE: To investigate whether total laparoscopic hysterectomy (TLH) is equivalent to total abdominal hysterectomy (TAH) in women with treatment-naive endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: The Laparoscopic Approach to Cancer of the Endometrium (LACE) trial was a multinational, randomized equivalence trial conducted between October 7, 2005, and June 30, 2010, in which 27 surgeons from 20 tertiary gynecological cancer centers in Australia, New Zealand, and Hong Kong randomized 760 women with stage I endometrioid endometrial cancer to either TLH or TAH. Follow-up ended on March 3, 2016. INTERVENTIONS: Patients were randomly assigned to undergo TAH (n = 353) or TLH (n = 407). MAIN OUTCOMES AND MEASURES: The primary outcome was disease-free survival, which was measured as the interval between surgery and the date of first recurrence, including disease progression or the development of a new primary cancer or death assessed at 4.5 years after randomization. The prespecified equivalence margin was 7% or less. Secondary outcomes included recurrence of endometrial cancer and overall survival. RESULTS: Patients were followed up for a median of 4.5 years. Of 760 patients who were randomized (mean age, 63 years), 679 (89%) completed the trial. At 4.5 years of follow-up, disease-free survival was 81.3% in the TAH group and 81.6% in the TLH group. The disease-free survival rate difference was 0.3% (favoring TLH; 95% CI, -5.5% to 6.1%; P = .007), meeting criteria for equivalence. There was no statistically significant between-group difference in recurrence of endometrial cancer (28/353 in TAH group [7.9%] vs 33/407 in TLH group [8.1%]; risk difference, 0.2% [95% CI, -3.7% to 4.0%]; P = .93) or in overall survival (24/353 in TAH group [6.8%] vs 30/407 in TLH group [7.4%]; risk difference, 0.6% [95% CI, -3.0% to 4.2%]; P = .76). CONCLUSIONS AND RELEVANCE: Among women with stage I endometrial cancer, the use of total abdominal hysterectomy compared with total laparoscopic hysterectomy resulted in equivalent disease-free survival at 4.5 years and no difference in overall survival. These findings support the use of laparoscopic hysterectomy for women with stage I endometrial cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00096408; Australian New Zealand Clinical Trials Registry: CTRN12606000261516.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Janda M, Gebski V, Davies LC, et al. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017. PMID: 28350928. doi:10.1001/jama.2017.2068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。